
Chinese clinical mass spectrometry company founded in 2015 and based in the Zhejiang University Zijin start-up park in Hangzhou, Zhejiang, with 13.5 million yuan of registered capital and recognised as a Hangzhou overseas investment attraction enterprise and a healthcare near-unicorn. Integrates mass spectrometry instruments, reagent products, testing services and big data analysis into complete clinical laboratory solutions, combining cross-platform technology and multi-omics data for precision diagnostics. Its main applications are newborn metabolic disease screening, endocrine disease testing and early cancer diagnosis, and it raised a 300 million yuan Series C round.
留下您的评分